Table Info

Table 1.

Overview of Abs undergoing to treat SARS-CoV-2

Ab	Isolating tropism	Potential efficacy (µg/mL)	Binding affinity (nmol/L, Kd)	Potential binding domain	In vivo activity	Cross-reactivity against SARS-CoV	References
CR3022	Humanized	0.114	6.3–115	RBD	N/A	Present	[4]
CV-30	Humanized	0.003	3.6	RBD	N/A	absent	[114, 115]
COVA1-12	Humanized	1.4	2.7	RBD	N/A	absent	[10, 116]
CB6	Humanized	0.026	2.49	RBD	N/A	absent	[117]
CCL12.1	Humanized	0.0222	5.83	RBD	N/A	absent	[10]
4A8	Humanized	0.61	91.7	RBD	NTD	absent	[9, 103]

List of Abs undergoing to treat SARS-CoV-2, revealing potential isolating source tropism, binding specificity, affinity, and cross-reactivity against SARS-CoV strain

Declarations

Acknowledgments

The author is thankful to Tsinghua University, School of Life Science (SLS) for providing all kind of facilities to prepare the manuscript.

Author contributions

KH and RS are the main authors of this manuscript who designed the manuscript and content outlines; MUA, MSIK, and ZUR provide technical assistance and revise the manuscript critically; ZF and OSA provide critical overview and support in figure drafting. SB carefully overviewed and revised the manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Galluccio F, Ergonenc T, Garcia Martos A, Allam AE, Pérez-Herrero M, Aguilar R, et al. Treatment algorithm for COVID-19: a multidisciplinary point of view. Clin Rheumatol. 2020;39:2077–84. [DOI] [PubMed] [PMC]

Yang Y, Peng F, Wang R, Yange M, Guan K, Jiang T, et al. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434. [DOI] [PubMed] [PMC]

Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26:483–95. [DOI] [PubMed] [PMC]

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11. [DOI] [PubMed] [PMC]

Haneef K, Asghar MU, Ali A. Novel immunogenomic insights of corona virus disease (COVID-19): available potential immunotherapeutics, current challenges, immune cell recognition and ongoing managerial strategies. Biomed Res Ther. 2020;7:3906–15. [DOI]

Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17:647–9. [DOI] [PubMed] [PMC]

Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020;16:1239–42. [DOI] [PubMed] [PMC]

Xie M, Chen Q. Insight into 2019 novel coronavirus-an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020;94:119–24. [DOI] [PubMed] [PMC]

Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther. 2020;3:109–14. [DOI] [PubMed] [PMC]

10.

Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, et al. Antibody response and therapy in COVID-19 patients: significance in vaccine development. bioRxiv 2020080166 [Preprint]. 2020 [cited 2020 Aug 6]. Available from: https://www.preprints.org/manuscript/202008.0166/v1

11.

Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400. [DOI] [PubMed] [PMC]

12.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490–6. [DOI] [PubMed] [PMC]

13.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020;6:1192–8. [DOI] [PubMed] [PMC]

14.

Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26:917–21. [DOI] [PubMed] [PMC]

15.

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92:1890–901. [DOI] [PubMed] [PMC]

16.

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1–9. [DOI] [PubMed]

17.

Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CL^pro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10:313–9. [DOI] [PubMed] [PMC]

18.

Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine. 2008;43:336–41. [DOI] [PubMed]

19.

Flajnik MF, Du Pasquier L. Evolution of innate and adaptive immunity: can we draw a line? Trends Immunol. 2004;25:640–4. [DOI] [PubMed]

20.

Feng Y, Wang Y, Zhang S, Haneef K, Liu W. Structural and immunogenomic insights into B-cell receptor activation. J Genet Genomics. 2020;47:27–35. [DOI] [PubMed]

21.

Shaheen S, Wan Z, Haneef K, Zeng Y, Jing W, Liu W. B cell mechanosensing: a mechanistic overview. Adv Immunol. 2019;144:23–63. [DOI] [PubMed]

22.

Shaheen S, Wan Z, Li Z, Chau A, Li X, Zhang S, et al. Substrate stiffness governs the initiation of B cell activation by the concerted signaling of PKCβ and focal adhesion kinase. Elife. 2017;6:e23060. [DOI] [PubMed] [PMC]

23.

Xu C, Wan Z, Shaheen S, Wang J, Yang Z, Liu W. A PI_4,5P2-derived “gasoline engine model” for the sustained B cell receptor activation. Immunol Rev. 2019;291:75–90. [DOI] [PubMed]

24.

Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318:E736–41. [DOI] [PubMed] [PMC]

25.

De Biasi S, Lo Tartaro D, Meschiari M, Gibellini L, Bellinazzi C, Borella R, et al. Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. Eur J Immunol. 2020;50:1283–94. [DOI] [PubMed]

26.

Wan Z, Shaheen S, Chau A, Zeng Y, Liu W. Imaging: gear up for mechano-immunology. Cell Immunol. 2020;350:103926. [DOI] [PubMed]

27.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451–4. [DOI] [PubMed] [PMC]

28.

Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole; a potential novel addition to the COVID-19 treatment regimen. Arch Acad Emerg Med. 2020;8:e40. [PubMed] [PMC]

29.

Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–62. [DOI] [PubMed]

30.

Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, et al. T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis. 2020;222:198–202. [DOI] [PubMed] [PMC]

31.

Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. [DOI] [PubMed] [PMC]

32.

Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21:1107–18. [DOI] [PubMed]

33.

Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160:261–8. [DOI] [PubMed] [PMC]

34.

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–62. [DOI] [PubMed] [PMC]

35.

Jia R, Wang X, Liu P, Liang X, Ge Y, Tian H, et al. Mild cytokine elevation, moderate CD4⁺ T cell response and abundant antibody production in children with COVID-19. Virol Sin. 2020;35:734–43. [DOI] [PubMed] [PMC]

36.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–8. [DOI] [PubMed] [PMC]

37.

Kalimuddin S, Tham CYL, Qui M, de Alwis R, Sim JXY, Lim JME, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y). 2021;2:682–8.e4. [DOI] [PubMed] [PMC]

38.

Hendriks J, Xiao Y, Rossen JW, van der Sluijs KF, Sugamura K, Ishii N, et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8⁺ memory T cells and their capacity for secondary expansion. J Immunol. 2005;175:1665–76. [DOI] [PubMed]

39.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–5. [DOI] [PubMed] [PMC]

40.

Nassef Kadry Naguib Roufaiel M, Wells JW, Steptoe RJ. Impaired T-cell function in B-cell lymphoma: a direct consequence of events at the immunological synapse? Front Immunol. 2015;6:258. [DOI] [PubMed] [PMC]

41.

Arcanjo A, Logullo J, Menezes CCB, de Souza Carvalho Giangiarulo TC, Dos Reis MC, de Castro GMM, et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). Sci Rep. 2020;10:19630. [DOI] [PubMed] [PMC]

42.

Koenig LM, Boehmer DFR, Metzger P, Schnurr M, Endres S, Rothenfusser S. Blocking inflammation on the way: rationale for CXCR2 antagonists for the treatment of COVID-19. J Exp Med. 2020;217:e20201342. [DOI] [PubMed] [PMC]

43.

Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 1998;161:2195–200. [PubMed]

44.

Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8. [DOI] [PubMed]

45.

Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727–32. [DOI] [PubMed] [PMC]

46.

Noroozi R, Branicki W, Pyrc K, Łabaj PP, Pospiech E, Taheri M, et al. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions. Cytokine. 2020;133:155143. [DOI] [PubMed] [PMC]

47.

Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9:940–8. [DOI] [PubMed] [PMC]

48.

Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20:339–41. [DOI] [PubMed] [PMC]

49.

Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis. 2020;71:2688–94. [DOI] [PubMed] [PMC]

50.

Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16:1718–23. [DOI] [PubMed] [PMC]

51.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74. [DOI] [PubMed] [PMC]

52.

Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020;97:772–6. [DOI] [PubMed] [PMC]

53.

Dustin ML. What counts in the immunological synapse? Mol Cell. 2014;54:255–62. [DOI] [PubMed] [PMC]

54.

Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21:1506–16. [DOI] [PubMed] [PMC]

55.

Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971–7.e3. [DOI] [PubMed] [PMC]

56.

Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–81. [DOI] [PubMed] [PMC]

57.

Schultheiβ C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity. 2020;53:442–55.e4. [DOI] [PubMed] [PMC]

58.

Sánchez-Cerrillo I, Landete P, Aldave B, Sánchez-Alonso S, Sánchez-Azofra A, Marcos-Jiménez A, et al. COVID-19 severity associates with pulmonary redistribution of CD1c⁺ DCs and inflammatory transitional and nonclassical monocytes. J Clin Invest. 2020;130:6290–300. [DOI] [PubMed] [PMC]

59.

Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci. 2020;7:196. [DOI] [PubMed] [PMC]

60.

Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52:731–3. [DOI] [PubMed] [PMC]

61.

Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10:779–82. [DOI] [PubMed] [PMC]

62.

Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. 2020;35:1071–2. [DOI] [PubMed] [PMC]

63.

García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. [DOI] [PubMed] [PMC]

64.

Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202:356–60. [DOI] [PubMed] [PMC]

65.

Chen Y, Shan K, Qian W. Asians do not exhibit elevated expression or unique genetic polymorphisms for ACE2, the cell-entry receptor of SARS-CoV-2. bioRxiv 2020020258 [Preprint]. 2020 [cited 2020 Feb 24]. Available from: https://www.preprints.org/manuscript/202002.0258/v2

66.

Xu Y, Liu P, Gu J. Gastrointestinal and liver involvement in patients with COVID-19. Lancet Gastroenterol Hepatol. 2020;5:798–9. [DOI] [PubMed] [PMC]

67.

Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53:371–2. [DOI] [PubMed] [PMC]

68.

Shilts J, Wright GJ. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. bioRxiv 2020.07.25.221036 [Preprint]. 2020 [cited 2021 Jan 11]. Available from: https://www.biorxiv.org/content/10.1101/2020.07.25.221036v1

69.

Leonardi A, Rosani U, Brun P. Ocular surface expression of SARS-CoV-2 receptors. Ocul Immunol Inflamm. 2020;28:735–8. [DOI] [PubMed]

70.

Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75:2829–45. [DOI] [PubMed] [PMC]

71.

Kalita P, Padhi AK, Zhang KYJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020;145:104236. [DOI] [PubMed] [PMC]

72.

Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6:258–9. [DOI] [PubMed] [PMC]

73.

Ye Q, Wang B, Mao J. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect. 2020;80:607–13. [DOI] [PubMed] [PMC]

74.

Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42. [DOI] [PubMed] [PMC]

75.

Dashti-Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID-19. Pharmacotherapy. 2020;40:484–6. [DOI] [PubMed] [PMC]

76.

Santerre M, Arjona SP, Allen CN, Shcherbik N, Sawaya BE. Why do SARS-CoV-2 NSPs rush to the ER? J Neurol. 2021;268:2013–22. [DOI] [PubMed] [PMC]

77.

Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020;92:584–8. [DOI] [PubMed] [PMC]

78.

Robson B. The use of knowledge management tools in viroinformatics. Example study of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a therapeutic target. Comput Biol Med. 2020;125:103963. [DOI] [PubMed] [PMC]

79.

Li J, Guo M, Tian X, Liu C, Wang X, Yang X, et al. Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. bioRxiv 2020.03.31.019216 [Preprint]. 2020 [cited 2020 Jul 02]. Available from: https://www.biorxiv.org/content/10.1101/2020.03.31.019216v1

80.

Carter DC, Wright B, Jerome WG, Rose JP, Wilson E. A unique protein self-assembling nanoparticle with significant advantages in vaccine development and production. J Nanomater. 2020;2020:4297937. [DOI]

81.

Bharadwaj A, Wahi N, Saxena A, Chaudhary D. Proteome organization of COVID-19: illustrating targets for vaccine development. J Pure Appl Microbiol. 2020;14:831–40. [DOI]

82.

Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, et al. Immune-mediated approaches against COVID-19. Nat Nanotechnol. 2020;15:630–45. [DOI] [PubMed] [PMC]

83.

Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Linty F, Visser R, et al. Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19. bioRxiv 2020.05.18.099507 [Preprint]. 2020 [cited 2020 May 18]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.18.099507v1

84.

Kapur R, Kustiawan I, Vestrheim A, Koeleman CA, Visser R, Einarsdottir HK, et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood. 2014;123:471–80. [DOI] [PubMed] [PMC]

85.

Keam S, Megawati D, Patel SK, Tiwari R, Dhama K, Harapan H. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. Rev Med Virol. 2020;30:e2123. [DOI] [PubMed] [PMC]

86.

Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–8. [DOI] [PubMed] [PMC]

87.

Mozdzanowska K, Feng J, Gerhard W. Virus-neutralizing activity mediated by the fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol. 2003;77:8322–8. [DOI] [PubMed] [PMC]

88.

DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014;20:143–51. [DOI] [PubMed] [PMC]

89.

Jiang RD, Liu MQ, Chen Y, Shan C, Zhou YW, Shen XR, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020;182:50–8.e8. [DOI] [PubMed] [PMC]

90.

Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev. 2001;65:131–50. [DOI] [PubMed] [PMC]

91.

Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–5. [DOI] [PubMed]

92.

Daughaday CC, Brandt WE, McCown JM, Russell PK. Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors. Infect Immun. 1981;32:469–73. [DOI] [PubMed] [PMC]

93.

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. [DOI] [PubMed] [PMC]

94.

Ayouba A, Thaurignac G, Morquin D, Tuaillon E, Raulino R, Nkuba A, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020;129:104521. [DOI] [PubMed] [PMC]

95.

Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002; 42:165–79. [DOI] [PubMed]

96.

Chen Y, Li L. SARS-CoV-2: virus dynamics and host response. Lancet Infect Dis. 2020;20:515–6. [DOI] [PubMed] [PMC]

97.

Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. Lancet Infect Dis. 2020;20:633–4. [DOI] [PubMed] [PMC]

98.

Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51:843–51. [DOI] [PubMed] [PMC]

99.

Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis. 2020;26:1920–2. [DOI] [PubMed] [PMC]

100.

Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. 2020;7:157. [DOI] [PubMed] [PMC]

101.

To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–74. [DOI] [PubMed] [PMC]

102.

Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv 2020.05.08.083964 [Preprint]. 2020 [cited 2020 May 08]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.08.083964v1

103.

Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014;111:E2018–26. [DOI] [PubMed] [PMC]

104.

Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci. 2020;41:815–29. [DOI] [PubMed] [PMC]

105.

Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013;10:266. [DOI] [PubMed] [PMC]

106.

Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505–9. [DOI] [PubMed] [PMC]

107.

Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41:355–9. [DOI] [PubMed] [PMC]

108.

Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010–4. [DOI] [PubMed] [PMC]

109.

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:729–34. [DOI] [PubMed] [PMC]

110.

Rehman SU, Shafique L, Ihsan A, Liu Q. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. Pathogens. 2020;9:240. [DOI]

111.

Sardar R, Satish D, Birla S, Gupta D. Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis. bioRxiv 2020.03.21.001586 [Preprint]. 2020 [cited 2020 Mar 21]. Available from: https://www.biorxiv.org/content/10.1101/2020.03.21.001586v1

112.

Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368:630–3. [DOI] [PubMed] [PMC]

113.

Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020; 10:7448–64. [DOI] [PubMed] [PMC]

114.

Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 2020;53:98–105.e5. [DOI] [PubMed] [PMC]

115.

Hurlburt NK, Wan YH, Stuart AB, Feng J, McGuire AT, Stamatatos L, et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv 2020.06.12.148692 [Preprint]. 2020 [cited 2020 Oct 27]. Available from: https://www.biorxiv.org/content/10.1101/2020.06.12.148692v1

116.

Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv 2020.05.12.088716 [Preprint]. 2020 [cited 2020 Aug 07]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.12.088716v1

117.

Mi T, Burgess K. Striking similarities between CDRs in some mAbs that neutralize COVID-19. ACS Med Chem Lett. 2020;11:1663–6. [DOI] [PubMed] [PMC]